Why the study?
Do new oral anticoagulants (NOACs) improve efficacy and safety compared to vitamin K antagonists in patients with atrial fibrillation and venous thromboembolism?
Do new oral anticoagulants (NOACs) improve efficacy and safety compared to vitamin K antagonists in patients with atrial fibrillation and venous thromboembolism?
NOACs offer a safer and more convenient alternative to vitamin K antagonists for stroke prevention in atrial fibrillation and VTE management, particularly due to a significantly lower risk of intracranial hemorrhage.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sung-Won Jang (2016) conducted a review in Atrial fibrillation and venous thromboembolism. New Oral Anticoagulants (NOACs: dabigatran, rivaroxaban, apixaban, edoxaban) vs. Warfarin was evaluated on Stroke or systemic embolism (RR 0.81, 95% CI 0.73-0.91).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: